Silatecan
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00389480)
Timeline
Indications
Mechanism of action
- Topoisomerase I/IIINHIBITOR
Topoisomerase I/II inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ar-67
- ar-67
- ar-67
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01124539 | Phase 2 | Dec 1, 2009 | Arno Therapeutics, Duke University |
| NCT00956787 | Phase 2 | Jun 1, 2009 | Arno Therapeutics, University of Texas at Houston |
| NCT00389480 | Phase 1 | Oct 1, 2006 | Arch Medical Services Inc, Arno Therapeutics, University of Kentucky |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arno Therapeutics | For profit | 3 | 3 | 2 | 2006 |
| Arch Medical Services Inc | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1